Literature DB >> 19961615

A case of non-invasive serous adenocarcinoma at unilateral fimbria with spread to the peritoneal/uterine cavity: case report.

Yuki Fukumura1, Akiko Masaoka, Toshio Naito, Miki Kimura, Takashi Yao.   

Abstract

Recently, fimbriae have been identified as a possible arising site for the pelvic serous carcinoma (PSC) both in BRCA-positive and BRCA-negative women. Although non-invasive (intraepithelial) serous adenocarcinoma of the fimbria has been found in specimens obtained from prophylactic salphingo-oophorectomies in BRCA-positive women, there has not been any case report in clinical situation, since this type of tumor is usually detected after stromal invasion/widespread dissemination. We describe a 67-year-old woman with non-invasive serous adenocarcinoma located solely in the left fimbria. This case may suggest the benefit of endometrial cytology and detailed gross examination of fimbria for the early detection of fimbrial carcinoma. This case may provide evidence suggesting fimbrial intraepithelial adenocarcinoma is one cause of PSC.

Entities:  

Year:  2009        PMID: 19961615      PMCID: PMC3224938          DOI: 10.1186/1746-1596-4-43

Source DB:  PubMed          Journal:  Diagn Pathol        ISSN: 1746-1596            Impact factor:   2.644


  8 in total

1.  A candidate precursor to serous carcinoma that originates in the distal fallopian tube.

Authors:  Y Lee; A Miron; R Drapkin; M R Nucci; F Medeiros; A Saleemuddin; J Garber; C Birch; H Mou; R W Gordon; D W Cramer; F D McKeon; C P Crum
Journal:  J Pathol       Date:  2007-01       Impact factor: 7.996

2.  Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.

Authors:  David W Kindelberger; Yonghee Lee; Alexander Miron; Michelle S Hirsch; Colleen Feltmate; Fabiola Medeiros; Michael J Callahan; Elizabeth O Garner; Robert W Gordon; Chandler Birch; Ross S Berkowitz; Michael G Muto; Christopher P Crum
Journal:  Am J Surg Pathol       Date:  2007-02       Impact factor: 6.394

3.  The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.

Authors:  Fabiola Medeiros; Michael G Muto; Yonghee Lee; Julia A Elvin; Michael J Callahan; Colleen Feltmate; Judy E Garber; Daniel W Cramer; Christopher P Crum
Journal:  Am J Surg Pathol       Date:  2006-02       Impact factor: 6.394

4.  Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria.

Authors:  Dana R Semmel; Ann K Folkins; Michelle S Hirsch; Marisa R Nucci; Christopher P Crum
Journal:  Mod Pathol       Date:  2009-05-01       Impact factor: 7.842

Review 5.  Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause.

Authors:  Jurgen M J Piek; Peter Kenemans; René H M Verheijen
Journal:  Am J Obstet Gynecol       Date:  2004-09       Impact factor: 8.661

Review 6.  Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer.

Authors:  Yonghee Lee; Fabiola Medeiros; David Kindelberger; Michael J Callahan; Michael G Muto; Christopher P Crum
Journal:  Adv Anat Pathol       Date:  2006-01       Impact factor: 3.875

7.  Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention.

Authors:  Joseph W Carlson; Alexander Miron; Elke A Jarboe; Mana M Parast; Michelle S Hirsch; Yonghee Lee; Michael G Muto; David Kindelberger; Christopher P Crum
Journal:  J Clin Oncol       Date:  2008-09-01       Impact factor: 44.544

8.  Primary carcinoma of the fallopian tube--a retrospective analysis of 115 patients. Austrian Cooperative Study Group for Fallopian Tube Carcinoma.

Authors:  A Rosen; M Klein; M Lahousen; A H Graf; A Rainer; N Vavra
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

  8 in total
  1 in total

1.  P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas.

Authors:  Dinka Sundov; Ana Caric; Ivana Mrklic; Dijana Gugic; Vesna Capkun; Irena Drmic Hofman; Branka Petric Mise; Snjezana Tomic
Journal:  Diagn Pathol       Date:  2013-02-06       Impact factor: 2.644

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.